Lymphoma, Mucosa-Associated Lymphoid Type disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MALTOMA MCID: LYM129 MIFTS: 68	Lymphoma, Mucosa-Associated Lymphoid Type (MALTOMA) Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lymphoma, Mucosa-Associated Lymphoid Type

MalaCards integrated aliases for Lymphoma, Mucosa-Associated Lymphoid Type:

Name: Lymphoma, Mucosa-Associated Lymphoid Type ⁵⁷ ⁷³ ³⁶

Malt Lymphoma ⁵⁷ ¹¹ ⁵⁸ ⁷³ ⁵³ ⁵ ¹⁴ ¹⁶ ⁷⁵

Mucosa-Associated Lymphoid Tissue Lymphoma ¹¹ ⁵⁸ ⁷¹

Gastric Lymphoma, Primary ⁵⁷ ⁷³ ⁵³

Lymphoma, Malt, Somatic ⁵⁷ ⁷³ ³⁸

Extranodal Marginal Zone B-Cell Lymphoma ⁵⁸ ⁷¹

Marginal Zone B-Cell Lymphoma ⁷³ ⁷¹

Maltoma ⁵⁸ ⁷³

Mucosa-Associated Lymphatic Tissue Lymphoma ⁵⁸

Familial Primary Gastric Lymphoma ⁷¹

Primary Gastric Lymphoma ⁷³

Gastric Lymphoma ⁷¹

Characteristics:

Inheritance:

Malt Lymphoma: Multigenic/multifactorial ⁵⁸

Prevelance:

Malt Lymphoma: 1-9/1000000 (Europe) 1-9/100000 (United States, Europe) ⁵⁸

Age Of Onset:

Malt Lymphoma: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Malignant immunoproliferative diseases

Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lyphoma]

Orphanet: ⁵⁸

Rare haematological diseases

Sources

Summaries for Lymphoma, Mucosa-Associated Lymphoid Type

UniProtKB/Swiss-Prot: ⁷³ A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro- intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

MalaCards based summary: Lymphoma, Mucosa-Associated Lymphoid Type, also known as malt lymphoma, is related to thyroid lymphoma and burkitt lymphoma. An important gene associated with Lymphoma, Mucosa-Associated Lymphoid Type is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Signal Transduction and Innate Immune System. The drugs Chlorambucil and Tinidazole have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, b cells and thyroid, and related phenotypes are nausea and vomiting and hyperhidrosis

OMIM®: ⁵⁷ The concept of mucosa-associated lymphoid tissue (MALT) lymphomas was introduced by Isaacson and Wright (1983). MALT lymphomas are now recognized as a distinct subtype of non-Hodgkin lymphoma (605027). B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) are the most common form of lymphoma arising in extranodal sites, in most cases arising in the gastric mucosa (Isaacson and Spencer, 1995). (137245) (Updated 08-Dec-2022)

Orphanet: ⁵⁸ MALT (mucosa-associated lymphoid tissue) lymphoma is a rare form of malignant non-Hodgkin lymphoma (see this term) that affects B cells and grows at the expense of lymphoid tissue associated with mucous membranes, but also occurs, more rarely, in lymph nodes.

Disease Ontology: ¹¹ A marginal zone B-cell lymphoma that has material basis in mucosal tissue involved in antibody production.

Wikipedia: ⁷⁵ MALT lymphoma (MALToma) is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT),... more...

Sources

Related Diseases for Lymphoma, Mucosa-Associated Lymphoid Type

Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 722)

#	Related Disease	Score	Top Affiliating Genes
1	thyroid lymphoma	32.4	CD5 BCL6
2	burkitt lymphoma	32.3	IRF4 CXCR5 CXCL13 CD40 BCL6 BCL2
3	lymphoma	32.2	MALT1 IRF4 CXCR5 CXCL13 CD5 CD40
4	b-cell lymphoma	31.9	MALT1 IRF4 IGH FOXP1 CXCR5 CXCL13
5	gastric lymphoma	31.9	S100A8 MALT1 IRF4 CD5 CCR6 BIRC3
6	marginal zone b-cell lymphoma	31.9	S100A8 MALT1 KDM4C IRF4 FOXP1 CD5
7	lymphoma, hodgkin, classic	31.8	TRAF2 KDM4C IRF4 CD40 CCR6 BCL6
8	diffuse large b-cell lymphoma	31.7	KDM4C IRF4 CD5 CCR6 CARD11 BCL6
9	sjogren syndrome	31.6	CXCL13 CD40 CCR6
10	breast lymphoma	31.4	IRF4 CD5 BCL6 BCL2
11	lung lymphoma	31.4	MALT1 IRF4 CD5 BIRC3 BCL6
12	orofaciodigital syndrome viii	31.3	MALT1 KDM4C CD5 BIRC3 BCL6 BCL10
13	lymphoproliferative syndrome	31.3	CD5 CCR6 BCL6 BCL2
14	bladder lymphoma	31.3	CD5 BCL6
15	lymphoma, non-hodgkin, familial	31.3	MALT1 KDM4C IRF4 IGH CXCR5 CD5
16	hashimoto thyroiditis	31.2	CD40 CCR6 BCL2
17	plasmacytoma	31.2	IRF4 IGH CD5 CCND1 BCL2
18	follicular lymphoma	31.1	IRF4 IGH CXCR5 CD5 CD40 CCND1
19	waldenstroem's macroglobulinemia	31.1	IRF4 CD5 CD40 CCND1 BIRC3
20	gastrointestinal lymphoma	31.1	MALT1 CD5 CCND1 BIRC3 BCL6 BCL2
21	monoclonal gammopathy of uncertain significance	31.1	IRF4 CCR6 CCND1
22	gallbladder lymphoma	31.1	MALT1 CD5 BIRC3 BCL6
23	cryoglobulinemia	31.0	CXCL13 CD5 BCL2
24	orbit lymphoma	30.9	MALT1 FOXP1 BCL10
25	intraocular lymphoma	30.9	CXCR5 CXCL13 CD5 BCL6
26	acquired immunodeficiency syndrome	30.9	MADCAM1 CXCR5 CCND1 BCL6 BCL2
27	colon lymphoma	30.9	CD5 CCND1 BCL6 BCL2
28	extramedullary plasmacytoma	30.9	IRF4 CD5 CCND1
29	splenic marginal zone lymphoma	30.9	MALT1 CD5 CCR6 CCND1 CARD11 BIRC3
30	reticulosarcoma	30.9	IGH BCL6 BCL2
31	peripheral t-cell lymphoma	30.8	KDM4C CXCL13 CD5 CCR6 BCL6 BCL2
32	t-cell adult acute lymphocytic leukemia	30.8	IRF4 CD5 CCR6 CARD11
33	small intestine lymphoma	30.8	CD5 BCL6
34	lymphoplasmacytic lymphoma	30.8	IRF4 CD5 CCND1 CARD11 BCL6 BCL2
35	lymphatic system disease	30.8	KDM4C IRF4 CD5 CCR6 BCL6 BCL2
36	leukemia, chronic myeloid	30.8	KDM4C IRF4 CCR6 CCND1 BIRC3 BCL2
37	intravascular large b-cell lymphoma	30.8	BCL6 BCL2
38	angioimmunoblastic t-cell lymphoma	30.8	KDM4C IRF4 CXCR5 CXCL13 CD5 CCR6
39	leukemia, chronic lymphocytic 2	30.8	CD5 BCL2
40	mantle cell lymphoma	30.8	MALT1 KDM4C IRF4 IGH CD5 CD40
41	combined immunodeficiency	30.8	MALT1 IRF4 CD40 CCR6 CARD11 BCL10
42	leukemia, chronic lymphocytic	30.7	KDM4C IRF4 IGH CXCR5 CD5 CD40
43	primary central nervous system lymphoma	30.7	IGH CXCR5 CXCL13 BCL6
44	chronic lymphocytic leukemia/small lymphocytic lymphoma	30.7	CD5 CCND1 BCL6 BCL2
45	leukemia, acute myeloid	30.7	KDM4C CD5 CD40 CCR6 CCND1 BCL6
46	mature b-cell neoplasm	30.7	KDM4C IRF4 CD5 CD40 CCR6 CCND1
47	primary cutaneous t-cell non-hodgkin lymphoma	30.7	KDM4C CD5 CCR6
48	head and neck cancer	30.7	KDM4C CCR6 CCND1 BCL2
49	connective tissue disease	30.7	KDM4C IRF4 CD40 CCR6 CCND1 BCL2
50	lymphangioma	30.6	CCR6 CCND1 BCL2

Graphical network of the top 20 diseases related to Lymphoma, Mucosa-Associated Lymphoid Type:

Sources

Symptoms & Phenotypes for Lymphoma, Mucosa-Associated Lymphoid Type

Human phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

⁵⁸ ³⁰ (show all 18)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	nausea and vomiting ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002017
2	hyperhidrosis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000975
3	fatigue ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012378
4	fever ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001945
5	anemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001903
6	weight loss ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001824
7	pulmonary infiltrates ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002113
8	b-cell lymphoma ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012191
9	constipation ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002019
10	recurrent respiratory infections ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002205
11	visual impairment ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000505
12	abdominal pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002027
13	mediastinal lymphadenopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100721
14	abnormality of the thyroid gland ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000820
15	abnormal nasolacrimal system morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000614
16	posterior uveitis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012123
17	lymphadenopathy ⁵⁸		Occasional (29-5%)
18	gastric lymphoma ³⁰			HP:0045038

Clinical features from OMIM®:

137245 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.53	BCL10 BIRC3 CARD11 DUSP5
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.53	BCL10 CARD11 DUSP5 CD40
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.53	CD40

MGI Mouse Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.97	BCL10 BCL2 BCL6 BIRC3 CARD11 CCND1
2	immune system	MP:0005387	9.91	BCL10 BCL2 BCL6 BIRC3 CARD11 CCND1
3	hematopoietic system	MP:0005397	9.58	BCL10 BCL2 BCL6 BIRC3 CARD11 CCND1

Sources

Drugs & Therapeutics for Lymphoma, Mucosa-Associated Lymphoid Type

Drugs for Lymphoma, Mucosa-Associated Lymphoid Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Chlorambucil

Approved

Phase 3

305-03-3

2708

Tinidazole

Approved, Investigational

Phase 3

19387-91-8

5479

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Amoxicillin

Approved, Vet_approved

Phase 2

26787-78-0

33613

Loperamide

Approved

Phase 2

53179-11-6

3955

Esomeprazole

Approved, Investigational, Vet_approved

Phase 2

73590-58-6, 119141-88-7

9568614 4594

Bismuth subsalicylate

Approved, Vet_approved

Phase 2

14882-18-9

53629521 16682734

Clarithromycin

Approved

Phase 2

81103-11-9

84029

Metronidazole

Approved

Phase 2

443-48-1, 69198-10-3

4173

Tetracycline

Approved, Vet_approved, Withdrawn

Phase 2

60-54-8

5353990

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Ondansetron

Approved, Withdrawn

Phase 2

99614-02-5

4595

Carboplatin

Approved

Phase 1, Phase 2

41575-94-4

10339178 38904

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

4112 126941

Vorinostat

Approved, Investigational

Phase 1, Phase 2

149647-78-9

5311

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Ifosfamide

Approved

Phase 1, Phase 2

3778-73-2

3690

Panobinostat

Approved, Investigational

Phase 1, Phase 2

404950-80-7

6918837

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Alemtuzumab

Approved, Investigational

Phase 2

216503-57-0

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Etoposide

Approved

Phase 1, Phase 2

33419-42-0

36462

Doxycycline

Approved, Investigational, Vet_approved

Phase 2

564-25-0

54671203

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Lenograstim

Approved, Investigational

Phase 1, Phase 2

135968-09-1

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Ipilimumab

Approved

Phase 1, Phase 2

477202-00-9

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Oprelvekin

Approved, Investigational

Phase 1, Phase 2

145941-26-0

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Iron

Approved

Phase 2

7439-89-6

29936

Deferasirox

Approved, Investigational

Phase 2

201530-41-8

214348 5493381

Brentuximab vedotin

Approved, Investigational

Phase 1, Phase 2

914088-09-8

Interventional clinical trials:

(show top 50) (show all 164)

#	Name	Status	NCT ID	Phase	Drugs
1	Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma	Unknown status	NCT00003617	Phase 3	chlorambucil;clarithromycin;omeprazole;tinidazole
2	Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)	Completed	NCT00210353	Phase 3	chlorambucil (drug);rituximab+chlorambucil;rituximab
3	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
4	Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type	Unknown status	NCT00923663	Phase 2	Lenalidomide
5	A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma	Unknown status	NCT01678404	Phase 2	131I-rituximab
6	CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA	Completed	NCT00002682	Phase 2	Amoxicillin;Bismuth Subsalicylate;Clarithromycin;Metronidazole Hydrochloride;Omeprazole;Tetracycline Hydrochloride
7	A Clinico-pathological Phase II Study With Translational Elements to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae With Particular Reference to Chlamydia Species and the Effects of MALT Lymphoma Treatment With Tetracycline	Completed	NCT01010295	Phase 2	doxycycline (tetracycline)
8	Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma	Completed	NCT01015248	Phase 2	Rituximab and Bendamustine
9	Open-labeled, Multicenter Phase II Study of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients With Non-conjunctival Ocular Adnexal MALT Lymphoma	Completed	NCT01427114	Phase 2	rituximab, cyclophosphamide, vincristine, and prednisolone
10	Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type	Completed	NCT00373906	Phase 2	Bortezomib (Velcade)
11	Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)	Completed	NCT00373646	Phase 2	Thalidomide, Pharmion
12	A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma	Completed	NCT00117156	Phase 2	Fludarabine;Rituximab
13	Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone	Completed	NCT01514344	Phase 2	intralesional rituximab
14	Radiation Therapy Alone for Stage 1 and 2 MALT (Mucosa-Associated Lymphoid Tissue) Lymphoma	Completed	NCT04465162	Phase 2
15	Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142)	Completed	NCT00210327	Phase 2	Bortezomib (drug)
16	Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies	Completed	NCT01839916	Phase 2
17	Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies	Completed	NCT00867529	Phase 2
18	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
19	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
20	A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas	Completed	NCT02254772	Phase 1, Phase 2	SD-101
21	Phase II Clinical Trial of Rituximab in Combination With Pegfilgrastim in Patients With Indolent B-Cell (CD-20-Positive) Lymphoma	Completed	NCT01682044	Phase 2
22	A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma	Completed	NCT00073918	Phase 2	cyclophosphamide;etoposide
23	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
24	A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas	Completed	NCT00054639	Phase 2
25	Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma	Completed	NCT00026182	Phase 2
26	A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)	Completed	NCT01110135	Phase 2	bendamustine hydrochloride;dexamethasone;etoposide
27	A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil	Completed	NCT00089011	Phase 2	fludarabine phosphate;mycophenolate mofetil;tacrolimus
28	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
29	Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies	Completed	NCT01093586	Phase 2	busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
30	Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation	Completed	NCT00049504	Phase 2	cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
31	A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma	Completed	NCT00006473	Phase 2	oxaliplatin
32	A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma	Completed	NCT00601718	Phase 1, Phase 2	vorinostat;ifosfamide;carboplatin;etoposide
33	A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma	Completed	NCT00918333	Phase 1, Phase 2	panobinostat;everolimus
34	A Phase II Study of CCI-779 in B-cell Lymphoma and CLL	Completed	NCT00290472	Phase 2	temsirolimus
35	Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma	Completed	NCT00244855	Phase 2	dexamethasone
36	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
37	A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy	Completed	NCT01075321	Phase 1, Phase 2	everolimus;lenalidomide
38	Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial	Completed	NCT00118352	Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
39	A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies	Completed	NCT00072514	Phase 2	gemcitabine hydrochloride;carboplatin;dexamethasone
40	A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant	Completed	NCT00058305	Phase 2	bryostatin 1;vincristine sulfate
41	A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease	Completed	NCT00003210	Phase 2
42	Phase II Study of MK-2206 in Patients With Relapsed Lymphoma	Completed	NCT01258998	Phase 2	Akt inhibitor MK2206
43	A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Completed	NCT01261247	Phase 2	panobinostat
44	A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation	Completed	NCT01529827	Phase 2	fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
45	A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies	Completed	NCT01384513	Phase 2	Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
46	High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma	Completed	NCT01177371	Phase 2	busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
47	A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation	Completed	NCT01789255	Phase 2	vorinostat;tacrolimus;cyclosporine;methotrexate
48	A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation	Completed	NCT01427881	Phase 2	cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
49	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
50	A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma	Completed	NCT01068392	Phase 2	Oxaliplatin, Prednisolone

Search NIH Clinical Center for Lymphoma, Mucosa-Associated Lymphoid Type

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Lymphoma, Mucosa-Associated Lymphoid Type cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Lymphoma, Mucosa-Associated Lymphoid Type:

Hematopoietic stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Lymphoma, Mucosa-Associated Lymphoid Type:

Bone marrow-derived hematopoietic stem cells

Sources

Genetic Tests for Lymphoma, Mucosa-Associated Lymphoid Type

Sources

Anatomical Context for Lymphoma, Mucosa-Associated Lymphoid Type

Organs/tissues related to Lymphoma, Mucosa-Associated Lymphoid Type:

MalaCards : Salivary Gland, B Cells, Thyroid, Thymus, Breast, Lung, Bone Marrow

Sources

Publications for Lymphoma, Mucosa-Associated Lymphoid Type

Articles related to Lymphoma, Mucosa-Associated Lymphoid Type:

(show top 50) (show all 5545)

#	Title	Authors	PMID	Year
1	Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. ⁵³ ⁶² ⁵⁷ ⁵	Willis TG...Dyer MJ	9989495	1999
2	The biology of low grade MALT lymphoma. ⁶² ⁵⁷	Isaacson PG...Spencer J	7629280	1995
3	Familial primary gastric lymphoma. ⁶² ⁵⁷	Hayoz D...Knecht H	8432445	1993
4	Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. ⁵	van Schothorst EM...Looijenga LH	10408400	1999
5	Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. ⁵	Fakruddin JM...Murty VV	10380920	1999
6	Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. ⁵⁷	Isaacson P...Wright DH	6193858	1983
7	Regression of rectal mucosa-associated lymphoid tissue (MALT) lymphoma after antibiotic treatments. ⁵³ ⁶²	Niino D...Ohshima K	20518898	2010
8	Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. ⁵³ ⁶²	Borthakur A...Dudeja PK	19714753	2010
9	The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. ⁵³ ⁶²	Murga Penas EM...Dierlamm J	19965626	2010
10	Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients. ⁵³ ⁶²	Ben Mansour K...Burucoa C	20302630	2010
11	Primary mucosa-associated lymphoid tissue lymphoma of the gallbladder: report of a case harboring API2/MALT1 gene fusion. ⁵³ ⁶²	Bisig B...de Leval L	19535128	2009
12	Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review. ⁵³ ⁶²	Razaq W...Grossbard ML	19525185	2009
13	Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma. ⁵³ ⁶²	Sumida T...Chayama K	19385974	2009
14	Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma. ⁵³ ⁶²	Noels H...Baens M	19279678	2009
15	BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. ⁵³ ⁶²	Dong G...Gao Z	18949449	2008
16	[Primary ocular adnexal lymphoproliferative lesions: clinicopathologic features and genetic alterations]. ⁵³ ⁶²	Dong LN...Gong LP	19159526	2008
17	Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. ⁵³ ⁶²	Ture-Ozdemir F...Mantzaris GJ	19189651	2008
18	Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. ⁵³ ⁶²	Kuo SH...Cheng AL	18628489	2008
19	[Frequency of genetic aberrations in mucosa-associated lymphoid tissue lymphoma of different sites]. ⁵³ ⁶²	Li BZ...Shi DR	19094584	2008
20	Significance of CXCR3 expression in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type for predicting responsiveness to Helicobacter pylori eradication. ⁵³ ⁶²	Yamamoto H...Nakamura S	18616679	2008
21	Influence of Helicobacter pylori infection persistence on bcl-2 expression in gastric mucosa inflammatory cells. ⁵³ ⁶²	Brajsa K...Dominis M	19175059	2008
22	Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas. ⁵³ ⁶²	Deutsch AJ...Neumeister P	18561120	2008
23	Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. ⁵³ ⁶²	Nakamura S...Du MQ	18445693	2008
24	CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. ⁵³ ⁶²	Barone F...Pitzalis C	18354239	2008
25	Chromosomal instability in gastric mucosa-associated lymphoid tissue lymphomas: a fluorescent in situ hybridization study using a tissue microarray approach. ⁵³ ⁶²	Bernasconi B...Terracciano LM	18234275	2008
26	T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. ⁵³ ⁶²	Coornaert B...Beyaert R	18223652	2008
27	Chromosomal translocations involving BCL6 in MALT lymphoma. ⁵³ ⁶²	Ye H...Du MQ	18166802	2008
28	[Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type]. ⁵³ ⁶²	Li BZ...Shi DR	18346354	2007
29	Generation of a new monoclonal antibody against MALT1 by genetic immunization. ⁵³ ⁶²	Maestre L...Roncador G	17451356	2007
30	Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression. ⁵³ ⁶²	Kuo SH...Cheng AL	17167822	2007
31	CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma. ⁵³ ⁶²	Tasaki K...Abe M	17300675	2007
32	MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas. ⁵³ ⁶²	Borovecki A...Dominis M	17199743	2007
33	Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10. ⁵³ ⁶²	Lobry C...Weil R	17213322	2007
34	Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study. ⁵³ ⁶²	Joao C...Cabecadas J	17222250	2007
35	Deviated VH4 immunoglobulin gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at other sites, but is not found in thyroid diffuse large B-cell lymphomas. ⁵³ ⁶²	Sato Y...Yoshino T	16980947	2006
36	The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. ⁵³ ⁶²	Remstein ED...Kurtin PJ	17122510	2006
37	MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast. ⁵³ ⁶²	Talwalkar SS...Medeiros LJ	16917511	2006
38	High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. ⁵³ ⁶²	Chen YW...Srivastava G	16772602	2006
39	Functional polymorphisms of CD14 and toll-like receptor 4 in Taiwanese Chinese with Helicobacter pylori-related gastric malignancies. ⁵³ ⁶²	Wu MS...Lin JT	17086894	2006
40	Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma. ⁵³ ⁶²	Gallardo F...Serrano S	16784987	2006
41	Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein. ⁵³ ⁶²	Nakagawa M...Hosokawa Y	16572204	2006
42	Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). ⁵³ ⁶²	Zhou Y...Du MQ	16512826	2006
43	Cytogenetic and clinicopathological characterization by fluorescence in situ hybridization on paraffin-embedded tissue sections of twenty-six cases with malignant lymphoma of small intestine. ⁵³ ⁶²	Yoshida N...Taniwaki M	16484127	2006
44	MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells. ⁵³ ⁶²	Sagaert X...De Wolf-Peeters C	16341151	2006
45	Frequency of chromosomal aneuploidies and deletions of the RB and TP53 genes in MALT lymphomas harboring the t(14;18)(q32;q21). ⁵³ ⁶²	Murga Penas EM...Dierlamm J	16364768	2006
46	A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus. ⁵³ ⁶²	Yeh PY...Cheng AL	16280327	2006
47	[Expression of bcl-10 protein in MALT lymphoma]. ⁵³ ⁶²	Li L...Li FY	16545185	2005
48	Overexpression of caspase recruitment domain (CARD) membrane-associated guanylate kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma. ⁵³ ⁶²	Nakamura S...Iida M	16177990	2005
49	BCL10 expression in ocular adnexal lymphomas. ⁵³ ⁶²	Vejabhuti C...Chang CC	16310461	2005
50	Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). ⁵³ ⁶²	Yeh KH...Cheng AL	15845895	2005

Sources

Genes for Lymphoma, Mucosa-Associated Lymphoid Type

Genes related to Lymphoma, Mucosa-Associated Lymphoid Type (5 elite genes):

(show top 50) (show all 69)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BCL10	BCL10 Immune Signaling Adaptor	Protein Coding	1278.05	Molecular basis known ⁵⁷ Pathogenic ⁵ Gene fusion ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	9989495 10380920 10408400 (more) 25922601 10319863 15682443 11445840 16545185 15634591 18346354 19080537 16310461 14674990 16341151 15337797 10665648 16395405 18949449 15845895 19279678 11120333 16440771 16123224 16280327 11836626 11748643 12651604 11605060 17167822 10942247 10797525 15711920 18628489 16344587 11376806 11372735 11090634 10790217 10725326 16572204 17213322 14716524 11493332 11066079 16127295 11262391 10886211 19094584 16177990 15878976 11356195 19535128 17540779 11466612 12017308 16784987 15540895 11079291 11425462 16775419
2	MALT1	MALT1 Paracaspase	Protein Coding	370.66	Gene fusion ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15682443 14760068 10523859 (more) 11090634 16917511 12560219 15598810 16784987 14652825 18234275 16341151 17199743 11162514 19897720 10702396 16395405 16804917 11262391 11096264 10979968 19159526 19094584 18223652 16512826 17451356 20518898 19714753 19738055 15150097 19965626 17339192 16123224 15711920 19909374 17222250 15047736 11197361 10760689 16572204 10339464 15540895 10626814 15894263 16775419 11159207 19234489
3	BIRC3	Baculoviral IAP Repeat Containing 3	Protein Coding	367.96	Gene fusion ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10797525 11162514 19234489 (more) 11159207 15894263 10339464 11096264 11397650 16572204 16891304 15682443 15696476 17339192 12931213 14652825
4	IGH	Immunoglobulin Heavy Locus	Protein Coding	357.74	Gene fusion ⁵⁸ Novoseek inferred ⁵³	15703784 16364768
5	FOXP1	Forkhead Box P1	Protein Coding	357.04	Gene fusion ⁵⁸ DISEASES inferred ¹⁴	15703784
6	BCL6	BCL6 Transcription Repressor	Protein Coding	23.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11353050 9283593 15609396 (more) 15153535 17122510 11120333 18166802 9546062 19159526 12766583 18445693 16484127 11756145 15710572 16772602 9395180
7	S100A8	S100 Calcium Binding Protein A8	Protein Coding	16.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19385974 14742532 10391879 (more) 10364612 11427555 9706771 8903577 11316139 19040660 20302630 10535999 11513169
8	CARD11	Caspase Recruitment Domain Family Member 11	Protein Coding	15.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16177990
9	IRF4	Interferon Regulatory Factor 4	Protein Coding	15.1	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	15710572
10	CCND1	Cyclin D1	Protein Coding	14.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11699208 17300675 9543667 (more) 9395180 15710572 18303407 17018901 2249841 19525185
11	BCL2	BCL2 Apoptosis Regulator	Protein Coding	13.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9587934 11699208 8600035 (more) 7713486 7706514 1951841 7730485 9395180 14724650 19175059 10498595 9655306 1951637 12923379 2249841 1776108 10820341 8045037
12	CD5	CD5 Molecule	Protein Coding	13.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8561085
13	TRAF2	TNF Receptor Associated Factor 2	Protein Coding	11.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16512826
14	CXCL13	C-X-C Motif Chemokine Ligand 13	Protein Coding	11.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10562310 18354239
15	CXCR5	C-X-C Motif Chemokine Receptor 5	Protein Coding	11.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10562310
16	DUSP5	Dual Specificity Phosphatase 5	Protein Coding	11.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16980947
17	MADCAM1	Mucosal Vascular Addressin Cell Adhesion Molecule 1	Protein Coding	10.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11504840 14669317
18	CD40	CD40 Molecule	Protein Coding	10.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9767448 9814592
19	KDM4C	Lysine Demethylase 4C	Protein Coding	10.02	DISEASES inferred ¹⁴ ¹⁴
20	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	9.96	DISEASES inferred ¹⁴ ¹⁴
21	MIR142	MicroRNA 142	RNA Gene	8.59	DISEASES inferred ¹⁴ ¹⁴
22	HSPD1	Heat Shock Protein Family D (Hsp60) Member 1	Protein Coding	8.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11687439 14663101 11218410 (more) 15165254
23	TLR4	Toll Like Receptor 4	Protein Coding	8.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19189651 17086894
24	BIRC2	Baculoviral IAP Repeat Containing 2	Protein Coding	8.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11090634
25	CXCR3	C-X-C Motif Chemokine Receptor 3	Protein Coding	8.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18616679 15645433 12688353 (more) 18561120
26	TLR1	Toll Like Receptor 1	Protein Coding	8.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12519297
27	IGHV4-38-2	Immunoglobulin Heavy Variable 4-38-2	Protein Coding	8.04	DISEASES inferred ¹⁴
28	MIR200B	MicroRNA 200b	RNA Gene	8	DISEASES inferred ¹⁴ ¹⁴
29	MME	Membrane Metalloendopeptidase	Protein Coding	7.89	DISEASES inferred ¹⁴
30	MIR155	MicroRNA 155	RNA Gene	7.81	DISEASES inferred ¹⁴ ¹⁴
31	CD79A	CD79a Molecule	Protein Coding	7.72	DISEASES inferred ¹⁴
32	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	7.48	DISEASES inferred ¹⁴ ¹⁴
33	SPN	Sialophorin	Protein Coding	7.33	DISEASES inferred ¹⁴
34	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	7.27	DISEASES inferred ¹⁴
35	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	7.27	DISEASES inferred ¹⁴
36	TLR2	Toll Like Receptor 2	Protein Coding	7.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12519297
37	CR2	Complement C3d Receptor 2	Protein Coding	6.81	DISEASES inferred ¹⁴
38	TNFAIP3	TNF Alpha Induced Protein 3	Protein Coding	6.79	DISEASES inferred ¹⁴
39	ZAP70	Zeta Chain Of T Cell Receptor Associated Protein Kinase 70	Protein Coding	6.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15133473
40	CD80	CD80 Molecule	Protein Coding	6.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9767448
41	PAX5	Paired Box 5	Protein Coding	6.58	DISEASES inferred ¹⁴
42	CD19	CD19 Molecule	Protein Coding	6.45	DISEASES inferred ¹⁴
43	IGKC	Immunoglobulin Kappa Constant	Protein Coding	6.41	Novoseek inferred ⁵³	15122457
44	CD79B	CD79b Molecule	Protein Coding	6.36	DISEASES inferred ¹⁴
45	SIGLEC5	Sialic Acid Binding Ig Like Lectin 5	Protein Coding	6.35	DISEASES inferred ¹⁴ ¹⁴
46	MIR654	MicroRNA 654	RNA Gene	6.3	DISEASES inferred ¹⁴ ¹⁴
47	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	6.26	DISEASES inferred ¹⁴
48	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	6.25	DISEASES inferred ¹⁴
49	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	6.19	DISEASES inferred ¹⁴
50	FCRL4	Fc Receptor Like 4	Protein Coding	6.07	DISEASES inferred ¹⁴

Sources

Variations for Lymphoma, Mucosa-Associated Lymphoid Type

ClinVar genetic disease variations for Lymphoma, Mucosa-Associated Lymphoid Type:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	BCL10	NM_003921.5(BCL10):c.499dup (p.Ser167fs)	DUP	Pathogenic	6250	rs387906350	GRCh37: 1:85733512-85733513 GRCh38: 1:85267829-85267830
2	BCL10	NM_003921.5(BCL10):c.163dup (p.Ile55fs)	DUP	Pathogenic	6251	rs587776630	GRCh37: 1:85736483-85736484 GRCh38: 1:85270800-85270801
3	BCL10	NM_003921.5(BCL10):c.345del (p.Gly116fs)	DEL	Pathogenic	6252	rs587776631	GRCh37: 1:85736302-85736302 GRCh38: 1:85270619-85270619

Copy number variations for Lymphoma, Mucosa-Associated Lymphoid Type from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	119732	18	16100000	76117153	Gain	MALT1	Mucosa-associated lymphoid tissue lymphomas
2	206010	6	135101251	139048099	Loss	TNFAIP3	Mucosa-associated lymphoid tissue lymphomas

Sources

Expression for Lymphoma, Mucosa-Associated Lymphoid Type

Genes differentially expressed in tissues of Lymphoma, Mucosa-Associated Lymphoid Type patients vs. healthy controls: ³⁵ (show all 26)

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)	P value
1	APOA4	apolipoprotein A4	Stomach	-	6.08	0.008
2	DEFA5	defensin alpha 5	Stomach	-	5.85	0.050
3	ZG16	zymogen granule protein 16	Stomach	-	5.41	0.020
4	RBP2	retinol binding protein 2	Stomach	-	5.33	0.041
5	SPINK4	serine peptidase inhibitor Kazal type 4	Stomach	-	5.25	0.028
6	APOC3	apolipoprotein C3	Stomach	-	5.22	0.020
7	ALDOB	aldolase, fructose-bisphosphate B	Stomach	-	5.12	0.000
8	C17orf78	chromosome 17 open reading frame 78	Stomach	-	4.64	0.025
9	PCK1	phosphoenolpyruvate carboxykinase 1	Stomach	-	4.50	0.007
10	ITLN2	intelectin 2	Stomach	-	4.46	0.024
11	C3orf85	chromosome 3 open reading frame 85	Stomach	-	4.36	0.046
12	APOA1	apolipoprotein A1	Stomach	-	4.13	0.012
13	S100G	S100 calcium binding protein G	Stomach	-	4.13	0.016
14	ITLN1	intelectin 1	Stomach	-	4.03	0.013
15	SLC3A1	solute carrier family 3 member 1	Stomach	-	3.96	0.006
16	CPS1	carbamoyl-phosphate synthase 1	Stomach	-	3.90	0.050
17	ERICH4	glutamate rich 4	Stomach	-	3.87	0.039
18	SLC17A4	solute carrier family 17 member 4	Stomach	-	3.72	0.028
19	SLC7A9	solute carrier family 7 member 9	Stomach	-	3.71	0.029
20	OTC	ornithine transcarbamylase	Stomach	-	3.70	0.034
21	TMPRSS15	transmembrane serine protease 15	Stomach	-	3.58	0.042
22	FABP1	fatty acid binding protein 1	Stomach	-	3.51	0.032
23	CASP16P	caspase 16, pseudogene	Stomach	-	3.49	0.003
24	CREB3L3	cAMP responsive element binding protein 3 like 3	Stomach	-	3.44	0.039
25	MEP1B	meprin A subunit beta	Stomach	-	3.38	0.041
26	SLC2A2	solute carrier family 2 member 2	Stomach	-	3.08	0.012

Search GEO for disease gene expression data for Lymphoma, Mucosa-Associated Lymphoid Type.

Sources

Pathways for Lymphoma, Mucosa-Associated Lymphoid Type

Pathways related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 24)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.62	BCL2 BIRC3 CCND1 CCR6 CXCL13 CXCR5
2	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.32	TRAF2 S100A8 MALT1 MADCAM1 IRF4 CD40
3	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.28	TRAF2 CXCR5 CXCL13 CD40 CCR6 CCND1
4	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.19	BCL2 BCL6 BIRC3 CCND1 CD40 IRF4
5	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.57	TRAF2 MALT1 CD40 CARD11 BCL10
6	Apoptosis and Autophagy ³ Show member pathways Activation and oligomerization of BAK protein ⁶⁶ AIF Pathway ⁶⁴ Nanomaterial induced apoptosis ⁷⁴ Pro-survival signaling of neuroprotectin D1 ⁷⁴ vRNA Synthesis ⁶⁶	12.15	TRAF2 MALT1 BIRC3 BCL2 BCL10
7	CD28 Signaling in T-Helper Cell ⁶⁴ Show member pathways ICos-ICosL Pathway in T-Helper Cell ⁶⁴	12.11	MALT1 CD40 CARD11 BCL10
8	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.01	MALT1 CCND1 CARD11 BCL10
9	Vitamin D receptor pathway ⁷⁴	11.92	S100A8 IRF4 CD40 CCND1 BCL6
10	DNA damage response (only ATM dependent) ⁷⁴	11.8	CCND1 BCL6 BCL2
11	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.79	IRF4 CCND1 BCL6 BCL2
12	Notch Signaling Pathways ⁶⁵	11.78	CCND1 BCL6 BCL2
13	Allograft rejection ⁷⁴	11.74	CXCR5 CXCL13 CD40
14	Small cell lung cancer ⁷⁴	11.72	TRAF2 CCND1 BIRC3 BCL2
15	NF-kappaB Signaling ³	11.68	TRAF2 MALT1 IRF4 CXCR5 CARD11 BCL6
16	Innate Lymphoid Cells Differentiation ⁶⁵	11.66	IRF4 CXCR5 CCR6
17	C-MYB transcription factor network ⁶¹	11.66	CCND1 BIRC3 BCL2
18	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic TNFs/NF-kB/IAP pathway ²²	11.53	TRAF2 CD40 BIRC3 BCL2
19	ATF-2 transcription factor network ⁶¹	11.49	DUSP5 CCND1 BCL2
20	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.47	BCL6 CD40 CXCR5 IRF4
21	THC Differentiation Pathway ⁶⁴	11.4	MALT1 CD40 CARD11 BCL10
22	BCR signaling pathway ⁶¹	11.27	MALT1 CARD11 BCL6 BCL10
23	CD40/CD40L signaling ⁶¹	11.1	TRAF2 CD40 BIRC3
24	Genes associated with the development of rheumatoid arthritis ⁷⁴	10.87	CD40 CCR6

Sources

GO Terms for Lymphoma, Mucosa-Associated Lymphoid Type

Cellular components related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	polkadots	GO:0002096	9.26	MALT1 BCL10
2	CBM complex	GO:0032449	9.1	MALT1 CARD11 BCL10

Biological processes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of apoptotic process	GO:0042981	10.07	BCL10 BCL2 BIRC3 CARD11 MALT1 TRAF2
2	immune system process	GO:0002376	10.03	S100A8 MALT1 IRF4 CD40 CARD11 BCL6
3	regulation of inflammatory response	GO:0050727	10	S100A8 FOXP1 BIRC3 BCL6
4	B cell activation	GO:0042113	9.97	MALT1 CXCR5 CD40
5	chemotaxis	GO:0006935	9.96	S100A8 CXCR5 CXCL13 CCR6
6	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	9.93	BCL10 BIRC3 CARD11 CD40 MALT1 TRAF2
7	B cell proliferation	GO:0042100	9.92	CD40 CARD11 BCL6 BCL2
8	negative regulation of B cell apoptotic process	GO:0002903	9.88	FOXP1 BCL6 BCL2
9	chronic inflammatory response	GO:0002544	9.87	S100A8 CXCL13
10	positive regulation of B cell proliferation	GO:0030890	9.86	CD40 CARD11 BCL6 BCL2
11	regulation of immune response	GO:0050776	9.85	CD40 CARD11 BCL6
12	positive regulation of T cell activation	GO:0050870	9.78	BCL10 CARD11 MALT1
13	regulation of immunoglobulin production	GO:0002637	9.75	TRAF2 CD40
14	response to fungus	GO:0009620	9.7	MALT1 BCL10
15	regulation of T cell receptor signaling pathway	GO:0050856	9.69	MALT1 BCL10
16	positive regulation of interleukin-2 production	GO:0032743	9.56	TRAF2 MALT1 IRF4 CARD11
17	regulation of programmed cell death	GO:0043067	9.54	BIRC3 BCL2
18	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.4	TRAF2 S100A8 MALT1 CD40 CARD11 BCL10